Jacques Mallet

USPTO Granted Patents = 23 (Patent Applications = 3)

CIPO Patents = 2

EPO Patents = 2 (Patent Applications = 4)

Average Co-Inventor Count = 3.4

ph-index = 7

Forward Citations = 215(Granted Patents)

Company Filing History:

Centre National De La Recherche Scientifique

patents

4 out of 247

Rhone-poulenc Rorer S.a.

Institut National De Recherche Pour L'agriculture, L'alimentation L'environnement

Assistance Publique-hopitaux De Paris

patents

9. 1 out of 31

Institut National De La Sante Et De La Recherche Medicale (inserm)

patents

10. 1 out of 4

Institut Du Cerveau Et De La Moelle Epiniere

patents

11. 2 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1997-2025

Loading Chart...

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12419971 - Diet controlled expression of a nucleic acid encoding a pro-apoptotic protein (2025-09-23),

2. 8431119 - Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative diseases (2013-04-30),

3. 8119119 - Non-integrative and non-replicative lentivirus, preparation and uses thereof (2012-02-21),

4. 8071753 - RNAi mediated expression inhibition of a cholinergic protein (2011-12-06),

5. 7749973 - Methods of gene transfer to astrocytes with mokola virus pseudotyped lentivirus vectors (2010-07-06),

6. 7341718 - Neuronal gene transfer of adenovirus and herpes virus vectors (2008-03-11),

7. 7273854 - Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative disorders (2007-09-25),

8. 7241591 - Adenovirus comprising a gene coding for glutathione peroxidase (2007-07-10),

9. 7018628 - Vectors derived from baculovirus and use for transferring nucleic acids into nerve cells of vertebrates (2006-03-28),

10. 6998474 - Polypeptides of the 'basic helix-loop-helix' bHLH family, corresponding nucleic acid sequences (2006-02-14),

11. 6943016 - Human adult astrocytes, their preparation and uses thereof (2005-09-13),

12. 6756523 - Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system particularly in brain (2004-06-29),

13. 6723315 - Method for treating amyotrophic lateral sclerosis (2004-04-20),

14. 6685934 - Recombinant adenoviruses coding for basic fibroblast growth factors (BFGF) (2004-02-03),

15. 6632427 - Adenoviral-vector-mediated gene transfer into medullary motor neurons (2003-10-14),

Title: **Jacques Mallet: Pioneer in Pharmaceutical Innovations**

Introduction

Jacques Mallet is a prominent inventor based in Paris, France, known for his significant contributions to the field of pharmaceuticals. With an impressive portfolio of 22 patents, Mallet has dedicated his career to developing innovative solutions for complex medical issues, particularly neurodegenerative diseases.

Latest Patents

His recent patents showcase his commitment to advancing medical science. One notable invention is a pharmaceutical composition that targets the p53 protein or its gene, with methods designed specifically for treating neurodegenerative diseases. This groundbreaking work aims to provide new therapeutic options for patients suffering from these debilitating conditions. Additionally, he has developed a non-integrative and non-replicative recombinant lentivirus. This invention is crucial for gene transfer applications – enabling the modification of tissues or cells in mammals, including critical areas such as the central nervous system and ocular spheres.

Career Highlights

Throughout his career, Jacques Mallet has collaborated with major pharmaceutical companies, including Aventis Pharma S.A. and Rhône-Poulenc Rorer S.A. These affiliations have allowed him to apply his innovative ideas in real-world settings, further advancing the pharmaceutical industry.

Collaborations

Mallet has worked alongside esteemed colleagues, including Frédéric Revah and Michel Perricaudet. These collaborations have contributed to the development of new therapies and the advancement of scientific research in the pharmaceutical sector.

Conclusion

Jacques Mallet’s contributions to the pharmaceutical field exemplify the spirit of innovation. His work not only advances scientific understanding but also holds the potential to improve the lives of countless individuals affected by neurodegenerative diseases. Through his patents and collaborations, Mallet continues to drive the industry forward, establishing himself as a key figure in medical research and development.

This text is generated by artificial intelligence and may not be accurate.